Enanta Pharmaceuticals Inc
NASDAQ:ENTA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4.26
15.16
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. The company is headquartered in Watertown, Massachusetts and currently employs 155 full-time employees. The company went IPO on 2013-03-21. The firm is engaged in development of small molecule drugs for the treatment of viral infections and liver diseases. The firm has clinical candidates for the disease targets, including respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH). The firm has discovered glecaprevir, a protease inhibitor discovered and developed for the treatment of chronic hepatitis C virus (HCV). Glecaprevir is co-formulated direct-acting antiviral (DAA), a combination treatment for HCV infection under the tradenames: MAVYRET and MAVIRET. Its product candidates also include EDP-514, EDP-305 and EDP-938. The firm's subsidiary is Enanta Pharmaceuticals Security Corporation.
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. The company is headquartered in Watertown, Massachusetts and currently employs 155 full-time employees. The company went IPO on 2013-03-21. The firm is engaged in development of small molecule drugs for the treatment of viral infections and liver diseases. The firm has clinical candidates for the disease targets, including respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH). The firm has discovered glecaprevir, a protease inhibitor discovered and developed for the treatment of chronic hepatitis C virus (HCV). Glecaprevir is co-formulated direct-acting antiviral (DAA), a combination treatment for HCV infection under the tradenames: MAVYRET and MAVIRET. Its product candidates also include EDP-514, EDP-305 and EDP-938. The firm's subsidiary is Enanta Pharmaceuticals Security Corporation.
Revenue: Enanta reported Q2 revenue of $17.1 million, down from $17.8 million in the prior year.
Net Loss: The company posted a net loss of $31.2 million ($1.47 per share), an improvement from a $37.7 million loss last year.
Pipeline Progress: Data from the Phase II pediatric RSV study (RSVPEDs) is expected in the second half of 2024, and Phase IIa EDP-323 RSV data is anticipated in Q3 2024.
Expense Guidance: R&D expense guidance was raised to $125–145 million, and G&A expense guidance rose to $50–60 million, both reflecting increased pipeline investment.
Cash Position: Enanta ended the quarter with approximately $300 million in cash and marketable securities, expected to fund operations into Q3 2027.
Immunology Expansion: The company aims to select a KIT inhibitor candidate for CSU by Q4 2024 and introduce a second immunology program this year.
Patent Litigation: Legal expenses increased due to the ongoing patent infringement case against Pfizer, with a potential trial expected around year-end.
